Servier India Launches Free Biomarker Testing for Cancer

In a major boost to India’s cancer diagnostics ecosystem, Servier India has launched a national initiative aimed at improving access to biomarker testing for patients with Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA). This strategic programme—built on partnerships with genomic labs MedGenome and Strand Life Sciences—aims to bring cutting-edge precision oncology tools closer to patients, particularly those in the public healthcare sector and underserved areas.

Expanding Access to Molecular Testing in India

The initiative addresses a long-standing gap in India’s cancer care landscape—limited availability of quality molecular diagnostics outside urban centres. Most patients, especially in tier-2 and tier-3 cities, have minimal access to genetic testing which is vital for targeted cancer treatment.

To counter this, Servier India will offer a customised biomarker testing panel focusing on IDH1 and IDH2 mutations—key genetic markers involved in AML and CCA.

• These tests will be offered free of cost to patients receiving treatment in government hospitals,
• and at subsidised rates for others under Servier’s patient-assistance programme.

This marks an important step toward equitable access in cancer diagnosis.

Focus on Precision Oncology

The core principle behind this initiative is precision oncology—a modern approach where treatment is tailored to the individual’s cancer genetics. By identifying mutations like IDH1 and IDH2, clinicians can,

• Select targeted therapies that are more effective,
• Avoid generic treatments that may have lower efficacy, and
• Improve patient outcomes and survival chances.

Servier India emphasizes that early molecular testing leads to timely treatment decisions, which can make a significant difference in the prognosis of these aggressive cancers.

Key Cancer Types: AML and CCA

Acute Myeloid Leukaemia (AML)

• A fast-progressing blood cancer affecting white blood cells.
• Requires prompt and accurate diagnosis for effective treatment.
• IDH mutations in AML are associated with specific targeted therapies.

Cholangiocarcinoma (CCA)

• A rare cancer originating in the bile ducts.
• Often diagnosed late, hence precision treatment is critical.
• Genetic profiling is increasingly vital for therapy planning in such cancers.

By prioritising these two cancers, the initiative targets diseases where biomarker-guided treatments can offer substantial benefits.

Collaborative Delivery Model

The initiative’s success lies in a collaborative approach. Servier India has partnered with,

• MedGenome and Strand Life Sciences for genomic testing and diagnostic logistics,
• Clinicians and hospitals for patient identification and sample coordination, and
• Patient networks for outreach, counselling and treatment navigation.
• This last-mile delivery model ensures minimal delays between diagnosis and treatment, enabling quicker therapeutic intervention.

‘Servier Care’: Holistic Patient Support

This biomarker testing programme is integrated under the ‘Servier Care’ initiative—an umbrella patient-support platform by Servier India. It includes,

• Free or subsidised diagnostics,
• Financial support for eligible patients,
• Assistance with access to medications, and
• Guidance through the treatment journey.

The programme reinforces the company’s goal of building a comprehensive and compassionate healthcare ecosystem, especially for economically disadvantaged patients.